U
Ute Jungwirth
Researcher at University of Bath
Publications - 30
Citations - 1609
Ute Jungwirth is an academic researcher from University of Bath. The author has contributed to research in topics: In vivo & Apoptosis. The author has an hindex of 16, co-authored 26 publications receiving 1332 citations. Previous affiliations of Ute Jungwirth include University of Vienna & Lund University.
Papers
More filters
Journal ArticleDOI
Anticancer activity of metal complexes: involvement of redox processes.
Ute Jungwirth,Christian R. Kowol,Bernhard K. Keppler,Christian G. Hartinger,Walter Berger,Petra Heffeter +5 more
TL;DR: The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.
Journal ArticleDOI
Resistance against novel anticancer metal compounds: differences and similarities
Petra Heffeter,Ute Jungwirth,Michael A. Jakupec,Christian G. Hartinger,Markus Galanski,Leonilla Elbling,Michael Micksche,Bernhard K. Keppler,Walter Berger +8 more
TL;DR: This review summarizes the current knowledge on drug resistance mechanisms against novel metal compounds (including platinum, arsenic, ruthenium, gallium, titanium, copper, and lanthanum drugs), and addresses the question whether there might exist a general metal-drug resistance phenotype.
Journal ArticleDOI
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Petra Heffeter,Katharina Böck,Bihter Atil,Mir Alireza Hoda,Wilfried Körner,Caroline Bartel,Ute Jungwirth,Bernhard K. Keppler,Michael Micksche,Walter Berger,Gunda Koellensperger +10 more
TL;DR: The data indicate that KP1019 and KP1339 rapidly enter tumor cells, followed by binding to larger protein complexes/organelles, and consequently a unique mode of action for the ruthenium drugs investigated.
Journal ArticleDOI
Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity
Wolfgang Kandioller,Evelyn Balsano,Samuel M. Meier,Ute Jungwirth,Simone Göschl,Alexander Roller,Michael A. Jakupec,Walter Berger,Bernhard K. Keppler,Christian G. Hartinger +9 more
TL;DR: Organometallic Ru(II), Os(II) and Rh(III) complexes of lapachol induce apoptosis in human tumour cell lines in the low μM range by a mode of action involving oxidative stress, especially in the case of the ruthenium compound.
Journal ArticleDOI
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
Petra Heffeter,Bihter Atil,Kushtrim Kryeziu,Diana Groza,Gunda Koellensperger,Wilfried Körner,Ute Jungwirth,Thomas Mohr,Bernhard K. Keppler,Walter Berger +9 more
TL;DR: The combination of KP1339 with sorafenib displays promising activity in vitro and in vivo especially against human hepatoma models, and several mechanisms were found to underlie these multifaceted synergistic activities.